IL12B
Interleukin-12 subunit beta
As of the edition of 20 October 2026, IL12B (interleukin-12 subunit beta, UniProt P29460) has 5 drugs tested at it and 9 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P29460
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 20
- Disease areas
- Digestive system; Skin and connective tissue; Immune system; Bones, joints and muscles; Inherited and neonatal; Heart and blood vessels; Nervous system; Eye
- Registered trials of its drugs
- 161
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Went quiet | 1 |
| Status not established | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ustekinumab | Marketed | Phase 4 | Ended 2021 |
| Briakinumab | Went quiet | Phase 3 | none listed |
| Ebdarokimab | Active | Phase 3 | none listed |
| GNR-068 | Active | Phase 3 | none listed |
| AVT04 | Status not established | Phase 3 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 5 |
| Undetermined | 1 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| AbbVie | Route A |
| Johnson & Johnson | Route B |
| Abbott | Route A |
The other 6 companies at IL12B
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at IL12B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.